Investors weren't happy with the company's latest effort at capital-raising. Relay Therapeutics (RLAY -13.83%), one of a clutch of biotech companies that are developing treatments in the wide and potentially lucrative oncology field, didn't have a good Wednesday on the stock market. This followed the latest news about the biotech company's upcoming secondary share issue, which many investors consider to be unacceptably dilutive. On the back of that news, Relay's stock closed the day almost 14% lower, in con ...

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 4,285,714 share ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The clinical benefit rate (CBR) was 57% in heavily pretreated patients. RLY-2608 is a pan-mutant and isoformselective inhibitor of PI3Kα. Oppenheimer downgraded Relay Therapeutics, noting the upcoming data from competitors. "We believe that approved PI ...

Shares of Relay Therapeutics (RLAY) soared 52.4% on Sept. 9 after the company announced positive interim data from the early-stage study of its lead investigational candidate, RLY-2608, to treat heavily pretreated breast cancer patients. The enrolled population included PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer (MBC) patients who received the combo regimen of twice-daily, 600 mg dose of RLY-2608 and AstraZeneca's (AZN) Faslodex (fulvestrant). Interim data from the study showed t ...

CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of c ...

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 1.08% to 40,781.71 while the NASDAQ rose 0.76% to 16,818.23. The S&P 500 also rose, gaining, 0.95% to 5,459.48. Check This Out: Top 3 Financials Stocks That Could Blast Off In September Leading and Lagging Sectors Consumer discretionary shares surged by 1.8% on Monday. In trading on Monday, communication services shares rose by just 0.1%. Top Headline U.S. wholesale inventories increased by 0 ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The data showed that despite heavy pre-treatment, patients with PI3Kα-mutated, HR+, HER2- locally advanced or metasta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share RLAY Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | --- | --- | --- | |------------------------|-------|-----------|------- ...

Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2024 Approxim ...

Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2024 Approximately $688 million in cash, cash equivalents and investments at end of Q2 2024, expected to fund operat ...